Abstract Body

Background

Studies have identified an increased risk of dolutegravir (DTG) resistance in people with nucleos(t)ide (NRTI) resistance after transitioning from non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) to tenofovir/lamivudine/dolutegravir (TLD). However, the frequency of this occurrence in programmatic settings, as well as the impact of NRTI resistance on emergence of DTG resistance minority variants, is not known. 

Methods

We conducted a prospective cohort study in Uganda and South Africa of adults with HIV (age ≥18) who were in care at public-sector clinics and were transitioned from NNRTI-based ART to TLD. Participant HIV-1 RNA viral loads (VL) were measured on the date of TLD transition and again 24 and 48 weeks later. Illumina next-generation sequencing (NGS) of pol was performed on all specimens with a VL>500 copies/mL. We examined the frequency of HIV-1 resistance mutations at 2%, 5%, and 20% thresholds. Genotypic susceptibility scores (GSS) were calculated using the Stanford algorithm, ranging from 0 (resistant) to 1 (susceptible). We defined resistance as GSS­≤0.5.

Results

We enrolled 999 participants (median age 44 years (IQR 36-51 years), 61% female) who had been on ART for a median of 7 years (IQR 5-11 years) prior to TLD transition. At TLD transition, 3% of participants (n=27/999) had a VL>500 copies/mL of which 25 (93%) were successfully sequenced, and 15 had resistance to both tenofovir (TDF) and lamivudine (3TC) at the 2%, 5% and 20% thresholds. Of these 15 with confirmed resistance, ten (67%) achieved viral suppression (<50 copies/mL) by 48 weeks (compared to 90% among those with viral suppression at transition, (P=0.015)), two never suppressed, and three were lost to follow-up. At 24 weeks, 1% of participants (n=11/999) underwent NGS, of whom 10 were successfully sequenced. Of these 10, one participant had resistance to both TDF and 3TC at 2-20% thresholds and resuppressed by 48 weeks. At 48 weeks, 2% of participants (n=20/999) had a VL>500 copies/mL and underwent NGS. However, no study participants, including those with resistance to TDF and 3TC at the time of TLD transition or 24 weeks later, had resistance to DTG at the 2-20% thresholds after one year on TLD.

Conclusions

In a cohort of approximately 1,000 people who transitioned from NNRTI-containing ART to TLD in public sector clinics in Uganda and South Africa, resistance to TDF and FTC at transition was not associated with emergent DTG resistance, including minority variants.

Table or Figure